Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute

项目总结/摘要 我的职业生涯致力于改善淋巴瘤患者的预后，并利用我的 专业知识，以改善临床试验在我的家乡机构和国家的行为。我培养了一种真诚的 致力于成功的NCI资助的临床试验，这往往解决最关键的临床问题 并不断挑战护理标准，以改善全国范围内的患者结果。Winship 埃默里大学癌症研究所是国家临床试验网络牵头学术参与机构， 拥有强大的临床试验组合，每年约有1000名患者参加多个治疗研究， 遍布亚特兰大大都会区我是淋巴瘤疾病项目的联合主任， 淋巴瘤治疗模式工作组，以及数据安全性监查委员会主席。在这些角色 我可以影响我的诊所和整个癌症中心的临床试验。我还担任了审判的领导 通过ECOG-ACRIN淋巴瘤委员会（PrE 0404，A051201），最近被任命为 代表ECOG-ACRIN淋巴瘤委员会参加真实的世界证据工作组，并担任联合主席 他是温希普的ETCTN联盟的淋巴瘤疾病特异性工作组的成员。因此，我很好- 定位于显著影响NCI资助的研究的成功。我会利用R50的资源 研究专家奖，通过改善NCTN的访问和应计来改善NCI资助的临床试验 和ETCTN试验在亚特兰大和格鲁吉亚通过加强现有的合作与肿瘤学家 在整个州与温希普的社区外展和参与办公室。这将 包括扩大肿瘤委员会和国家方案拟订，1：1面对面和虚拟交流， 同事，并促进机会招募患者在NCTN研究更接近他们的家庭社区。 我将继续在全国范围内培养对临床感兴趣的初级研究者和受训者。 试验，并将确保他们能够获得NCTN和ETCTN的支持，以支持他们自己的发展 理念的我将利用我作为真实的世界证据领导者的经验来开发下一系列试验 在ECOG-ACRIN内部以及与全国各地的同事一起进行。我会继续成长 NCTN和ETCTN在Winship，并将确保同事继续有创新的研究， 招募患者，并拥有根据当前和未来的临床研究开发自己的项目所需的技能 需求

PROJECT SUMMARY/ABSTRACT I have devoted my career to the improvement of outcomes for patients with lymphoma and have utilized my expertise to improve clinical trial conduct at my home institution and nationally. I have developed a sincere commitment to the success of NCI-funded clinical trials, which often address the most critical clinical questions and which consistently challenge the standard of care in order to improve patient outcomes nationwide. Winship Cancer Institute of Emory University is a National Clinical Trial Network Lead Academic Participating Site and boasts a robust clinical trial portfolio, enrolling roughly 1000 patients per year to therapeutic studies at multiple sites throughout metropolitan Atlanta. I am the co-director of the lymphoma disease program, leader of the lymphoma treatment modality working group, and chair of the Data Safety Monitoring Committee. In these roles I can impact clinical trials in my clinic and throughout the Cancer Center. I have also assumed leadership of trials through the ECOG-ACRIN lymphoma committee (PrE0404, A051201), have recently been appointed to represent ECOG-ACRIN’s lymphoma committee on a Real World Evidence Working Group, and am the co-chair of the lymphoma disease specific working group for Winship’s ETCTN consortium. As a result, I am well- positioned to significantly impact of the success of NCI-funded studies. I will utilize the resources of the R50 Research Specialist Award to improve NCI-funded clinical trials through improved access and accrual to NCTN and ETCTN trials in Atlanta and the state of Georgia by strengthening existing collaborations with oncologists throughout the state in association with Winship’s Office of Community Outreach and Engagement. This will include expansion of tumor boards and national programming, 1:1 in person and virtual communication with colleagues, and facilitation of opportunities to enroll patients in NCTN studies closer to their home communities. I will continue to develop a pipeline of junior investigators and trainees nationwide who are interested in clinical trials and will ensure they have access to NCTN and ETCTN support to support development of their own concepts. I will develop the next series of trials by utilizing my experience as a leader in Real World Evidence cohorts, both within ECOG-ACRIN and with colleagues throughout the country. I will continue growth of the NCTN and ETCTN at Winship and will ensure that colleagues continue to have innovative studies to which to enroll patients and have the skills needed to develop their own projects based on current and future clinical needs.